BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8054282)

  • 1. Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck.
    Inki P; Joensuu H; Grénman R; Klemi P; Jalkanen M
    Br J Cancer; 1994 Aug; 70(2):319-23. PubMed ID: 8054282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Syndecan-1 expression has prognostic significance in head and neck carcinoma.
    Anttonen A; Kajanti M; Heikkilä P; Jalkanen M; Joensuu H
    Br J Cancer; 1999 Feb; 79(3-4):558-64. PubMed ID: 10027330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of syndecan-1 is induced by differentiation and suppressed by malignant transformation of human keratinocytes.
    Inki P; Larjava H; Haapasalmi K; Miettinen HM; Grenman R; Jalkanen M
    Eur J Cell Biol; 1994 Feb; 63(1):43-51. PubMed ID: 8005104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Syndecan-1: a new prognostic marker in laryngeal cancer.
    Pulkkinen JO; Penttinen M; Jalkanen M; Klemi P; Grénman R
    Acta Otolaryngol; 1997 Mar; 117(2):312-5. PubMed ID: 9105473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma.
    Rintala M; Inki P; Klemi P; Jalkanen M; Grénman S
    Gynecol Oncol; 1999 Dec; 75(3):372-8. PubMed ID: 10600292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced syndecan-1 expression is correlated with the histological grade of malignancy at the deep invasive front in oral squamous cell carcinoma.
    Kurokawa H; Zhang M; Matsumoto S; Yamashita Y; Tanaka T; Takamori K; Igawa K; Yoshida M; Fukuyama H; Takahashi T; Sakoda S
    J Oral Pathol Med; 2006 May; 35(5):301-6. PubMed ID: 16630294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas.
    Mikami S; Ohashi K; Usui Y; Nemoto T; Katsube K; Yanagishita M; Nakajima M; Nakamura K; Koike M
    Jpn J Cancer Res; 2001 Oct; 92(10):1062-73. PubMed ID: 11676857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma.
    Mukunyadzi P; Liu K; Hanna EY; Suen JY; Fan CY
    Mod Pathol; 2003 Aug; 16(8):796-801. PubMed ID: 12920224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The expression of cell adhesion molecule Syndecan-1 and E-candherin in laryngeal cancer].
    Li Y; Yang C
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2003 Dec; 17(12):736-8. PubMed ID: 15017723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of syndecan-1 expression in breast cancer.
    Leivonen M; Lundin J; Nordling S; von Boguslawski K; Haglund C
    Oncology; 2004; 67(1):11-8. PubMed ID: 15459490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome.
    Kumar-Singh S; Jacobs W; Dhaene K; Weyn B; Bogers J; Weyler J; Van Marck E
    J Pathol; 1998 Nov; 186(3):300-5. PubMed ID: 10211120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical localization of syndecan-1 in normal and pathological human uterine cervix.
    Inki P; Stenbäck F; Grenman S; Jalkanen M
    J Pathol; 1994 Apr; 172(4):349-55. PubMed ID: 8207616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between reduction of syndecan-1 expression and clinico-pathological parameters in squamous cell carcinoma of tongue.
    Ro Y; Muramatsu T; Shima K; Yajima Y; Shibahara T; Noma H; Shimono M
    Int J Oral Maxillofac Surg; 2006 Mar; 35(3):252-7. PubMed ID: 16280239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of syndecan-1 expression is associated with dysplastic oral epithelium.
    Soukka T; Pohjola J; Inki P; Happonen RP
    J Oral Pathol Med; 2000 Aug; 29(7):308-13. PubMed ID: 10947246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Syndecan-1 expression--a novel prognostic marker in pancreatic cancer.
    Juuti A; Nordling S; Lundin J; Louhimo J; Haglund C
    Oncology; 2005; 68(2-3):97-106. PubMed ID: 15886501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prognostic value of syndecan-1 in gastric cancer.
    Wiksten JP; Lundin J; Nordling S; Kokkola A; Haglund C
    Anticancer Res; 2000; 20(6D):4905-7. PubMed ID: 11326638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of syndecan-1 in malignancies.
    Inki P; Jalkanen M
    Ann Med; 1996 Feb; 28(1):63-7. PubMed ID: 8932508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. correlation with extracellular matrix components.
    Tsanou E; Ioachim E; Briasoulis E; Charchanti A; Damala K; Karavasilis V; Pavlidis N; Agnantis NJ
    J Exp Clin Cancer Res; 2004 Dec; 23(4):641-50. PubMed ID: 15743035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery.
    Anttonen A; Heikkilä P; Kajanti M; Jalkanen M; Joensuu H
    Lung Cancer; 2001 Jun; 32(3):297-305. PubMed ID: 11390011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Syndecan-1 expression in laryngeal cancer.
    Klatka J
    Eur Arch Otorhinolaryngol; 2002 Mar; 259(3):115-8. PubMed ID: 12003262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.